Interim Results

Source: RNS
RNS Number : 3367B
Cambridge Cognition Holdings PLC
22 August 2024
 

22 August 2024

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Unaudited Interim Results for the six months ended 30 June 2024

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces its unaudited interim results for the six-month period ended 30 June 2024 (the "period").


Financial highlights

Revenue is in line with the same period in 2023, which combined with a material reduction in costs, has reduced the adjusted operating loss significantly to £0.1 million (H1 2023: loss of £2.0 million):

·      Revenue of £5.6m (H1 2023: £6.0m)

·      Gross margin increased to 80.7% (H1 2023: 78.8%)

·      R&D expense decreased 35.2% to £1.4m (H1 2023: £2.2m)

·      Total operating expenditure decreased 35.3% to £5.4m (H1 2023: £8.4m)

·      Adjusted operating loss reduced by £1.9m to £0.1m (H1 2023: loss £2.1m)

·      Raised £2.6m to support the balance sheet and business development

·      Cash balances of £3.4m at 30 June 2024 (31 December 2023 £3.2m)


Operational highlights

Following a challenging end to 2023 and tough trading conditions during the period, we executed two critical actions to strengthen the underlying business:

·    Increased investment in the Group's commercial capability to enable it to exploit the central nervous systems ("CNS") clinical trials market through the combination of a clear product focus on cognitive assessments, CNS eCOA, and automated quality assurance solutions, and an expanded commercialisation team with deep sector experience and contacts.  The market is already large (estimated at $700 million in 2024) and is forecast to grow at 15% per annum from 2024 to 2029, and

·    A significant reduction of the cost base in H1 2024 has created a more agile business, which is better positioned to deliver sustainable profitability and cashflow as sales orders and revenues accelerate. 


Commenting on the results, Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"I'm pleased with the progress made during the first half as major steps were taken to strengthen our operation and business. The acquisitions of Clinpal and Winterlight are delivering new and expanded solutions and our recently enhanced commercial team is generating a growing pipeline of new business opportunities.  All these actions support our core objective to ensure we close 2024 with a secure balance sheet and a strong contracted order book of business to drive sustainable profitability and cashflow."

 

Investor webinar

Cambridge Cognition will host an online presentation and Q&A session at 16:00BST on 28 August 2024. This session is open to all existing and prospective shareholders. Those wishing to attend should email cog@hudsonsandler.com and they will be provided with log in details.

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be sent to cog@hudsonsandler.com.

 

Enquiries:

 

Cambridge Cognition Holdings plc 

Matthew Stork, Chief Executive Officer 

Tel: 012 2381 0700 

press@camcog.com 

 

Panmure Liberum Limited (NOMAD and Joint Broker) 

Will Goode / Freddy Crossley / Mark Rogers  

Rupert Dearden 

 

Tel: 020 7886 2968 

(Corporate Finance) 

(Corporate Broking) 

 

Dowgate Capital Limited (Joint Broker) 

David Poutney / Nicholas Chambers 

 

Tel: 020 3903 7715 

 

 

Hudson Sandler (Financial PR and IR) 

Dan de Belder / Hattie Dreyfus 

 

Tel: 020 7796 4133 

cog@hudsonsandler.com

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.


CHIEF EXECUTIVE OFFICER'S REVIEW

Business Review

During 2023 and early 2024, trading conditions remained challenging globally for the pharmaceutical sector, which has been impacted by inflationary trends and high interest rates.  Following a period of several years of revenue growth, we responded by delivering two critical actions to strengthen the business:

·      increasing commercial capability with increased capacity and deeper expertise and,

·      reducing the cost base of the business without impairing short-term growth potential.

Our objective is to deliver sustainable profitability (which we define as "adjusted operating profit") and sustained positive cashflow.

Increased commercial capability

To drive commercial performance, the Company recruited Alex Livingstone-Learmonth as Chief Commercial Officer in the first quarter.  Since his appointment he has recruited new team members with considerable experience and developed fresh contacts within the sector, increasing both the number and value of opportunities in the sales pipeline.  While contracted sales orders were modest in the first half, we expect to see an improvement as the year develops. 

We are focusing our efforts on product and service areas where we have a leading and/or highly differentiated position, particularly cognitive assessments (CANTAB and Winterlight), eCOA and AQUA, enabling the delivery of a tailored solution to challenging clinical studies where we demonstrate world-class domain expertise.

The recent acquisitions of Clinpal and Winterlight are contributing to the growth of the business. Combining the AQUA and Clinpal eCOA solutions with the Company's leading position in digital cognitive assessments, CANTAB, has given us a strong multi-product solution-oriented offering to meet clients' clinical development needs. 

These product launches, together with the strengthening of the commercial operations, has led to a deeper pipeline of new sales opportunities.  We are confident this will show increased sales orders in the second half of 2024. 

Reduced cost base

The second major initiative completed during the period has been to reduce the cost base to improve operating margins and cash flow generation.  Cost savings will not impact on prospects for short-term growth or operational delivery since they have been focused on integration synergies, trimming medium and long-term R&D projects and right-sizing operational and support teams. There has been a moderate increase in spending on commercialisation and maintenance of the healthcare offering.

During late 2023 we reduced the cost base by £1.5 million per annum.  In the first half of 2024 we completed a second review following integration of Clinpal and Winterlight.  This review reduced the cost base by an additional £2.0 million per annum, resulting in combined annual savings of £3.5 million per annum. 

 

Financial results

As announced previously at the time of the fundraising in May 2024 and in the trading update published in July 2024, market conditions remained challenging in H1 2024.  Revenue for the period was at a similar level to the same period in 2023. Nevertheless changes to the Company's cost base have delivered a significant positive improvement of £1.9 million at the adjusted operating profit level, with the adjusted operating loss reduced from £2.0 million in H1 2023 to £0.1 million for H1 2024.

The financial results for the period can be summarised as:

·      Revenue of £5.6m (H1 2023: £6.0m)

·      Gross margin increased to 80.7% (H1 2023: 78.8%)

·      R&D expense decreased 35.2% to £1.4m (H1 2023: £2.2m)

·      Total operating expenditure decreased 35.3% to £5.4m (H1 2023: £8.4m)

·      Adjusted operating loss reduced by £1.9 million to £0.1m (H1 2023: loss £2.1m)

·      Raised £2.6m to support the balance sheet and business development

·      Cash balances of £3.4m at 30 June 2024 (31 December 2023 £3.2m)

Revenue is recognised as services are delivered to clinical studies that are executed over several years.  This brings a degree of stability based on the strength of the order book and underpins future revenue generation.

This contracted order book provides good visibility over revenues for the full year, which are expected to be weighted to the second half of 2024. This is in line with historic performance.  At 30 June 2024 the order book was £14.6 million (31 Dec 2024: £17.2 million), but is expected to increase in H2. 

In May 2024 we raised £2.6 million by way of a placing of 6,561,057 new Ordinary Shares at 40 pence each with participation from both certain existing and new shareholders. We were delighted by the strong level of support shown for the Placing.  The funds raised enable us to grow technical and business development activities; to explore healthcare opportunities; for working capital purposes, including expansion of the commercial team; continuation of core development projects and provision of balance sheet strength.

At 30 June 2024 cash balances were £3.4 million (31 December 2023: £1.9million).

As announced previously, recruitment of a new CFO is progressing and we have added additional interim, senior financial resource. Further updates will be made in due course.

 

Outlook

The changes made to the commercial team have resulted in an expanded pipeline of new business opportunities.  As a result, we have increasing confidence that this will increase the long-term value of our contracted order book and underpin future revenue generation. 

We are beginning to see commercial benefits in the roll out of AQUA and the expanded eCOA product.  Both of these are generating new business opportunities. 

Costs continue to be managed tightly to support the existing product portfolio and grow the business.  We are now a more agile business, better positioned to deliver profitability and cashflow as sales orders and revenue accelerate. As a result of the actions taken during the year, combined with our clear growth strategy, we expect to deliver further success and value to our stakeholders.

 

Matthew Stork

Chief Executive Officer

CONDENSED CONSOLIDATED COMPREHENSIVE INCOME STATEMENT

For the six months ended 30 June 2024



6 months to 30 June 2024

6 months to 30 June 2023

Year to 31 December 2023



Unaudited

Unaudited

Audited


Note

 £'000

 £'000

 £'000

Revenue

4

5,603

6,039

13,515

Cost of sales


(1,079)

(1,281)

(2,717)

Gross profit


4,524

4,758

10,798

Research and development expense


(1,397)

(2,176)

(3,847)

Sales and marketing expense


(1,159)

(1,881)

(2,983)

Administrative expense


(2,726)

(3,408)

(6,139)

Non-recurring items

5

(144)

(940)

(1,456)

Total operating expense


(5,426)

(8,405)

(14,425)

Other operating income


63

230

322

Operating loss


(839)

(3,417)

(3,305)

Adjusted operating loss


(108)

(2,060)

(1,128)

Adjusting items1

5, 7

(731)

(1,357)

(2,177)

Operating loss


(839)

(3,417)

(3,305)

Interest receivable


12

6

16

Finance costs


(303)

(6)

(168)

Loss before tax


(1,130)

(3,417)

(3,457)

Tax credit/(expense)


10

106

(51)

Loss for the period


(1,120)

(3,311)

(3,508)

 


Other comprehensive (loss)/income


 



Items that may be reclassified subsequently to profit or loss:


 



Exchange differences on translation of foreign operations


(165)

41

(210)

Items that may not be reclassified subsequently to profit or loss:


 



Fair value movements in equity investments


-

-

107

Total comprehensive loss for the period


(1,285)

(3,270)

 


Loss per share (pence)


 



Basic

6

(3.2)

(9.6)

(10.1)

Diluted

6

(3.2)

(9.6)

(10.1)

 

All amounts are attributable to equity holders in the parent.

The above results relate to continuing operations.


 

1. Adjusting items comprise amortisation of acquisition related intangible assets of £276,000 (H1 2023: £282,000, 2023: £561,000), non-recurring items of £144,000 (H1 2023: £940,000, 2023: £1,456,000) and share-based payments of £311,000 (H1 2023: £135,000, 2023: £160,000). See note 5 for further details on non-recurring items and note 7 for intangible assets.



Consolidated statement of financial position

At 30 June 2024

 

 


At 30 June 2024

At 30 June 2023

At 31 December 2023

 


Unaudited

Unaudited

Audited

 

 

 £'000

 £'000

 £'000

Assets


 

 


Non-current assets


 

 


Goodwill


3,575

3,682

3,653

Other intangible assets

 7

3,727

4,404

4,089

Property, plant and equipment


68

177

133

Investments


156

49

156

Trade and other receivables


20

-

20

Total non-current assets


7,546

8,312

8,051

Current assets


 



Inventories


188

244

187

Trade and other receivables


2,655

3,698

2,417

Current tax receivable


210

138

351

Cash and cash equivalents


3,434

1,891

3,222

Total current assets


6,487

5,971

6,177

Total assets


14,283

Liabilities


 



Current liabilities


 



Trade and other payables


2,616

3,127

2,603

Deferred income on contracts with customers


6,500

10,158

7,699

Loans and borrowings


879

-

566

Current tax payable


19

-

99

Total current liabilities


10,014

13,285

10,967

Non-current liabilities


 



Loans and borrowings


1,475

-

1,978

Total non-current liabilities


1,475

-

1,978

Total liabilities


11,489

13,285

12,945

Equity


 



Share capital

8

417

349

350

Share premium


17,337

15,152

15,169

Other reserves


5,448

5,864

5,613

Own shares


(71)

(71)

(71)

Retained earnings


(20,587)

(20,296)

(19,778)

Total equity


2,544

998

1,283

Total liabilities and equity


14,283


 

Consolidated statement of changes in equity

At 30 June 2024

 

Share capital

Share premium

Other reserve

Own shares

Retained earnings

 

Total


£'000

£'000

£'000

£'000

£'000

£'000

At 1 January 2023 (audited)

312

11,151

5,823

(71)

(17,120)

95

Loss for the period

-

-

-

-

(3,311)

(3,311)

Other comprehensive income







Exchange differences on translation of foreign operations

-

-

41

-

-

41

Total comprehensive income/(loss) for the period

-

-

41

-

(3,311)

(3,270)

Transactions with owners







Issue of new shares in relation to business combination

34

3,966

-

-

-

4,000

Issue of new shares in relation to exercise of employee share options

3

35

-

-

-

38

Credit to equity for share-based payments

-

-

-

-

135

135

Transactions with owners

37

4,001

-

-

135

4,173

At 30 June 2023 (unaudited)

349

15,152

5,864

(71)

(20,296)

998

Loss for the period

-

-

-

-

(197)

(197)

Other comprehensive income/(loss)







Exchange differences on translation of foreign operations

-

-

(251)

-

-

(251)

Fair value movements on equity investments

-

-

-

-

107

107

Total comprehensive income/(loss) for the period

-

-

(251)

-

90

(341)

Transactions with owners







Issue of new shares in relation to exercise of employee share options

1

17

-

-

-

18

Credit to equity for share-based payments

-

-

-

-

25

25

Post-combination remuneration

-

-

-

-

309

309

Issue of warrants

-

-

-

-

274

274

Transactions with owners

1

17

-

-

608

626

At 31 December 2023 (audited)

350

15,169

5,613

(71)

(19,778)

1,283

Loss for the period

-

-

-

-

(1,120)

(1,120)

Other comprehensive loss







Exchange differences on translation of foreign operations

-

-

(165)

-

-

(165)

Total comprehensive loss for the period

-

-

(165)

-

(1,120)

(1,285)

Transactions with owners







Issue of new shares in relation to equity fundraising

65

2,559

-

-

-

2,624

Transaction costs relating to issue of share capital

-

(446)

-

-

-

(446)

Issue of new shares in relation to exercise of employee share options

2

55

-

-

-

57

Credit to equity for share-based payments

-

-

-

-

311

311

Transactions with owners

67

2,168

-

-

311

2,546

At 30 June 2024 (unaudited)

417

17,337

5,448

(71)

(20,587)

2,544


 

Consolidated statement of cash flows

For the 6 months ended 30 June 2024

 

 


6 months to 30 June 2024

6 months to 30 June 2023

Year to 31 December

 2023

 


Unaudited

Unaudited

Audited

 

Note

 £'000

 £'000

 £'000

Net cash flows used in operating activities

9

(1,583)

(3,499)

Investing activities


 



Acquisition of subsidiary, net of cash acquired


-

(3,002)

(3,002)

Interest received


12

6

16

Purchase of property, plant and equipment


-

(31)

(33)

Net cash flow generated from/(used in) investing activities


12

(3,027)

Financing activities


 



Proceeds from share issue


2,624

-

-

Transaction costs arising on issue of shares


(446)

-

-

Proceeds from borrowings, net of fees incurred


-

-

3,054

Proceeds from exercise of share options


57

38

56

Repayment of borrowings


(131)

-

(116)

Interest payments


(303)

-

(109)

Net cash flows generated from financing activities


1,801

38

Net increase/(decrease) in cash and cash equivalents


230

(6,488)

(5,101)

Cash and cash equivalents at start of period


3,222

8,322

8,322

Exchange differences on cash and cash equivalents


(18)

57

1

Cash and cash equivalents at end of period


3,434

1,891

 



NOTES TO THE INTERIM FINANCIAL STATEMENTS

 

1. General information

Cambridge Cognition Holdings plc ('the Company') and its subsidiaries (together, 'the Group') develops and markets digital solutions to assess brain health for sale worldwide, principally in the UK, the US and Europe.

 

The Company is a public limited company listed on the AIM market of the London Stock Exchange (symbol: COG) and is incorporated and domiciled in the UK. The address of its registered office is Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU.

 

The condensed consolidated interim financial statements were approved by the Board of Directors for issue on 21 August 2024. The condensed consolidated interim financial statements do not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006.

 

Statutory accounts of the Group for the year ended 31 December 2023 were approved by the Board of Directors on 31 May 2024 and delivered to the Registrar of Companies. The report of the auditors on those accounts was unqualified, did not contain an emphasis of matter paragraph and did not contain any statement under section 498 of the Companies Act 2006.

 

The condensed consolidated interim financial statements together with the comparative information for the six months ended 30 June 2023 have not been audited.

 

 

2. Accounting policies

 

2.1 Basis of preparation

As explained in note 2.1 of the Group's 2023 Annual Report, the Group made the following changes in presentation of the Consolidated Statement of Comprehensive Income and Consolidated Statement of Financial Position, which have resulted in restatements of prior period balances:

 

·    Consolidated Statement of Comprehensive Income: the Group previously combined Research and development expense, Sales and marketing expense and Administrative expense into Administrative expense (excluding non-recurring items). These have been separately presented to better present the nature of the expenditure. The overall operating loss for the period ended 30 June 2023 remains unchanged.

·   Consolidated Statement of Financial Position: the Group previously combined Goodwill and Other intangible assets within Intangible assets. These have been separately presented due to their materiality. The overall total and net asset balance at 30 June 2023 remain unchanged.

 

 

2.2 Going concern

The Group's forecasts and projections, taking account of reasonably possible changes in trading performance, support the conclusion that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future, a period of not less than twelve months from the date of this report.  The Directors believe that the Group will remain a going concern for the foreseeable future. The Group therefore continues to adopt the going concern basis in preparing its condensed consolidated interim financial statements.

 

 

2.3 Accounting policies

The accounting policies adopted in the preparation of the condensed consolidated interim financial statements are consistent with those followed in the preparation of the Group's consolidated financial statements for the year ended 31 December 2023.

 

 

3. Critical accounting judgements and key sources of estimation uncertainty

There have been no changes to the Group's significant judgements and estimates since the year ended 31 December 2023.

 

 

4. Segmental information

The analysis of revenue by product type is as follows:

 


6 months to 30 June 2024

6 months to 30 June 2023

Year to 31 December 2023


Unaudited

Unaudited

Audited


£'000

£'000

£'000

Software

2,693

2,872

6,532

Services

2,781

2,891

6,364

Hardware

129

276

619


5,603

6,039

13,515

 

 

5. Non-recurring items


6 months to 30 June 2024

6 months to 30 June 2023

Year to 31 December 2023


Unaudited

Unaudited

Audited


£'000

£'000

£'000

Acquisition and integration of Clinpal

(28)

214

570

Acquisition and integration of Winterlight

68

459

662

Restructuring

103

267

224


143

940

1,456

 

Non-recurring items are included on the consolidated income statement within administrative expenses.

 

Acquisition and integration of Clinpal

The Group acquired Clinpal in October 2022, as detailed in note 15.1 of the Group's 2023 Annual Report. As a result of the departure of a member of the Clinpal team in 2024 the Group reversed the related charge for retention payments. The Group will continue to accrue for retention payment amounts for the relevant members of staff who remain with the business until 31 December 2024.

 

Acquisition and integration of Winterlight

The Group acquired Winterlight Labs Inc in January 2023, as detailed in note 15.2 of the Group's 2023 Annual Report. Costs in the six months to 30 June 2024 relate to retention awards for key staff. This expense is anticipated to continue until July 2024.

 

Restructuring

The Group completed a significant, multi-department restructuring exercise in the six months to 30 June 2024. No further expense is anticipated in relation to this exercise.

 

 

6. Loss per share

Calculation of loss per share is based on the following loss and numbers of shares:

 

 

6 months to 30 June 2024

6 months to 30 June 2023

Year to 31 December 2023

 

Unaudited

Unaudited

Audited

 

 £'000

 £'000

 £'000

Loss attributable to owners of the Company for the purposes of:

 



Basic and diluted loss per share

(1,120)

(3,311)

(3,508)


 

 



6 months to 30 June 2024

6 months to 30 June 2023

Year to 31 December 2023


Unaudited

Unaudited

Audited

 

'000

'000

'000

Weighted average number of shares for the purposes of:

 



Basic and diluted loss per share

35,342

34,347

34,586

 

The diluted loss per share is considered to be the same as the basic loss per share. Potential dilutive shares are not treated as dilutive where they could result in an increased loss per share.

 

 


6 months to 30 June 2024

6 months to 30 June 2023

Year to 31 December 2023


Unaudited

Unaudited

Audited

 

Pence

Pence

Pence

Loss per share

 



Basic and diluted loss per share

(3.2)

(9.6)

(10.1)

 

See note 8 for details of the total number of shares in issue.

 

7. Goodwill and Other intangible assets

 

 

Acquisition related intangible assets

 

 

 

Goodwill

Technology based assets

Marketing based assets

Customer based assets

Licences

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

Cost







At 1 January 2023 (audited)

482

955

-

-

40

1,477

Acquired in business combinations

3,314

3,055

520

308

-

7,197

Exchange adjustment

(114)

(105)

(18)

(11)

-

(248)

At 30 June 2023 (unaudited)

3,682

3,905

502

297

40

8,426

Exchange adjustment

(29)

(26)

(4)

(3)

-

(62)

At 31 December 2023 (audited)

3,653

3,879

498

294

40

8,364

Exchange adjustment

(78)

(73)

(13)

(7)

-

(171)

At 30 June 2024 (unaudited)

3,575

3,806

485

287

40

8,193

Amortisation and impairment







At 1 January 2023 (audited)

-

32

-

-

24

56

Amortisation charge

-

249

17

16

3

285

Exchange adjustment

-

-

-

-

-

-

At 30 June 2023 (unaudited)

-

281

17

16

27

341

Amortisation charge

-

247

16

16

4

283

Exchange adjustment

-

(1)

-

(1)

-

(2)

At 31 December 2023 (audited)

-

527

33

31

31

622

Amortisation charge

-

245

16

15

3

279

Exchange adjustment

-

(9)

(1)

-

-

(10)

At 30 June 2024 (unaudited)

-

763

48

46

34

891

Net book value







At 1 January 2023 (audited)

482

923

-

-

16

1,421

At 30 June 2023 (unaudited)

3,682

3,624

485

282

13

8,086

At 31 December 2023 (audited)

3,653

3,352

465

263

9

7,742

At 30 June 2024 (unaudited)

3,575

3,043

437

241

6

7,302

 

 

8. Share capital

 


Number

£'000

At 1 January 2023 (audited)

31,170,093

312

Issue of new shares for the acquisition of Winterlight Labs Inc

3,445,595

34

Exercise of share options

237,145

3

At 30 June 2023 (unaudited)

34,852,833

349

Exercise of share options

107,276

1

At 31 December 2023 (audited)

34,960,109

350

Issue of new shares in relation to exercise of employee share options

189,263

2

Issue of new shares in relation to equity fundraising

6,561,057

65

At 30 June 2024 (unaudited)

41,710,429

417

 

All ordinary shares are issued and fully paid and carry equal voting and distribution rights. There are no other classes of shares.

 

During the six months to 30 June 2024, the Company issued 189,263 (6 months to 30 June 2023: 237,145) ordinary shares of 1 pence each with a nominal value of £1,893 (6 months to 30 June 2023: £2,371) pursuant to the exercise of shares options.

 

On 18 and 19 June 2024, the Company issued 6,561,057 ordinary shares of 1 pence each with a nominal value of £65,611 as part of an equity fundraise. Directly associated transaction fees of £446,000 were incurred which have been offset against share premium.

 

 

9. Reconciliation of operating result to operating cash flows

 

 

6 months to 30 June 2024

6 months to 30 June 2023

Year to 31 December 2023


Unaudited

Unaudited

Audited

 

 £'000

 £'000

 £'000

Loss before tax

(1,130)

(3,417)

(3,457)

Adjustments for:

 



Depreciation of property, plant and equipment

40

46

97

Impairment of property, plant and equipment

-

3

3

Amortisation of intangible assets

279

285

568

Share-based payments charge

311

135

160

Finance costs

303

-

168

Acquisition related expenses deferred amounts

-

202

318

Interest receivable

(12)

(6)

(16)

Research and Development expenditure tax credit

(13)

-

(73)

Operating cash flows before movements in working capital

(222)

(2,752)

(2,232)

(Increase)/decrease in inventories

-

(28)

29

Decrease/(increase) in trade and other receivables

(230)

1,242

2,235

Decrease/(increase) in trade and other payables

(13)

3

(445)

Decrease in deferred income from contracts with customers

(1,199)

(1,963)

(4,667)

Cash used in operations before tax

(1,664)

(3,498)

(5,080)

Taxation credit/(expense) less tax paid

81

(1)

113

Net cash flows used in operations

(3,499)

 

The share-based payment charge has increased to £311,000 in the six months to 30 June 2024 (six months to 30 June 2023: £135,000) due to the extension of the life of historic vested options in order to align to the Group's standard 10-year option life. This resulted in a one-off charge of £226,000.

 

 

10. Copies of interim financial statements

Copies of the interim financial statements are available from the Company at its registered office at Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU. The interim financial information document will also be available on the Company's website www.cambridgecognition.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR FLFVATEILFIS